Thank you for another successful year at ImVacS!
ImVacS 2014 brought together nearly 300 vaccine and immunotherapy experts from 20 countries to discuss new data, new approaches and novel science from industry, academia, regulatory, and research institutes. A special thank you to the speaking faculty, attendees, sponsors, exhibitors and media who helped make the ninth annual event such a great success!
Save the date for ImVacS 2015!
August 24-27, 2015 at the Marriot Long Warf in Boston, MA
Send us topic suggestions and speaker referrals for the 2015 ImVacS
The Regulatory Outlook for Future Vaccine Adjuvants
Norman W. Baylor, Ph.D., President and CEO, Biologics Consulting Group, Inc.
Synthetic Genomics to Address Emerging Threats and Global Supply Challenges
Bolyn Hubby, Ph.D., Senior Director, Head, Vaccine and Phage R&D, Synthetic Genomics Vaccines, Inc.
Putting Cancer in Check with Novel Immunomodulatory Strategies
Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center
Update from 2014 ASCO Meeting: Clinical Trials for Immunotherapy Combinations
Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
CAR T Cells from the Mouse Cage to the Patients’ Health
Zelig Eshhar, Ph.D., Professor, Immunology, The Weizmann Institute of Science
Each year, ImVacS brings vaccine professionals together from around the world to discuss the crucial issues surrounding vaccine development. Along with presenting a snapshot of where vaccines stand today, the meeting also provides an important venue for networking, information exchange, and establishing collaborations.
The “Novel Vaccines” meeting explores how vaccine development is being innovated in order to create more efficacious vaccines, such as using Systems Biology or Reverse Vaccinology. The use of adjuvants – their safety and mode of action – will also be discussed, as will DNA vaccines, Toll-Like Receptors, and novel modes of delivery. In addition, how improved vaccines are targeting infectious diseases will be addressed and updated.